| pubmed-article:2226986 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2226986 | lifeskim:mentions | umls-concept:C0020336 | lld:lifeskim |
| pubmed-article:2226986 | lifeskim:mentions | umls-concept:C0035331 | lld:lifeskim |
| pubmed-article:2226986 | lifeskim:mentions | umls-concept:C0220908 | lld:lifeskim |
| pubmed-article:2226986 | lifeskim:mentions | umls-concept:C0600688 | lld:lifeskim |
| pubmed-article:2226986 | pubmed:dateCreated | 1990-12-5 | lld:pubmed |
| pubmed-article:2226986 | pubmed:abstractText | All the patients (73) in the Rheumatology Department five year study of second line therapy who have taken hydroxychloroquine (Plaquenil) for rheumatoid arthritis for longer than 18 months were reviewed. These patients have their treatment dosage carefully monitored and have been receiving regular ophthalmic examinations. Most patients still taking the drug were assessed with a battery of tests for evidence of retinal toxicity. No retinal toxicity causing visual loss was found. On the basis of these results and a review of the recent literature we no longer routinely screen patients for hydroxychloroquine retinal toxicity in Cardiff. | lld:pubmed |
| pubmed-article:2226986 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2226986 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2226986 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2226986 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2226986 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2226986 | pubmed:issn | 0950-222X | lld:pubmed |
| pubmed-article:2226986 | pubmed:author | pubmed-author:JessopJ DJD | lld:pubmed |
| pubmed-article:2226986 | pubmed:author | pubmed-author:RichardsI MIM | lld:pubmed |
| pubmed-article:2226986 | pubmed:author | pubmed-author:MillsP VPV | lld:pubmed |
| pubmed-article:2226986 | pubmed:author | pubmed-author:MorsmanC DCD | lld:pubmed |
| pubmed-article:2226986 | pubmed:author | pubmed-author:LiveseyS JSJ | lld:pubmed |
| pubmed-article:2226986 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2226986 | pubmed:volume | 4 ( Pt 4) | lld:pubmed |
| pubmed-article:2226986 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2226986 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2226986 | pubmed:pagination | 572-6 | lld:pubmed |
| pubmed-article:2226986 | pubmed:dateRevised | 2009-11-3 | lld:pubmed |
| pubmed-article:2226986 | pubmed:meshHeading | pubmed-meshheading:2226986-... | lld:pubmed |
| pubmed-article:2226986 | pubmed:meshHeading | pubmed-meshheading:2226986-... | lld:pubmed |
| pubmed-article:2226986 | pubmed:meshHeading | pubmed-meshheading:2226986-... | lld:pubmed |
| pubmed-article:2226986 | pubmed:meshHeading | pubmed-meshheading:2226986-... | lld:pubmed |
| pubmed-article:2226986 | pubmed:meshHeading | pubmed-meshheading:2226986-... | lld:pubmed |
| pubmed-article:2226986 | pubmed:meshHeading | pubmed-meshheading:2226986-... | lld:pubmed |
| pubmed-article:2226986 | pubmed:meshHeading | pubmed-meshheading:2226986-... | lld:pubmed |
| pubmed-article:2226986 | pubmed:meshHeading | pubmed-meshheading:2226986-... | lld:pubmed |
| pubmed-article:2226986 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:2226986 | pubmed:articleTitle | Screening for hydroxychloroquine retinal toxicity: is it necessary? | lld:pubmed |
| pubmed-article:2226986 | pubmed:affiliation | Department of Ophthalmology, University Hospital of Wales, Cardiff. | lld:pubmed |
| pubmed-article:2226986 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2226986 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2226986 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2226986 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2226986 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2226986 | lld:pubmed |
